Curing operable stage i non-small cell lung cancer with stereotactic ablative body radiotherapy: The force awakens

Oncologist

Volumn 21, Issue 4, 2016, Pages 393-398

  Siva, Shankar ^a   Ball, David ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABLATION THERAPY; AGE; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); CYBERKNIFE; EDITORIAL; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HUMAN; LOBECTOMY; LUNG SURGERY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PATIENT AUTONOMY; PATIENT EDUCATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEREOTACTIC BODY RADIATION THERAPY; STUDY DESIGN; SURGICAL MORTALITY; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; CARCINOMA, NON-SMALL-CELL LUNG; PATHOLOGY; PROCEDURES; RADIOSURGERY;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; NEOPLASM STAGING; RADIOSURGERY;

EID: 84963894071     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0477     Document Type: Editorial

References (37)

1. Morrison R, Deeley T, Cleland W. The treatment of carcinoma of the bronchus: A clinical trial to compare surgery and supervoltage radiotherapy. Lancet 1963;281:683-684.
2. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 nonsmall cell lung cancer. Ann Thorac Surg 1995;60: 615-622; discussion 622-623.
3. Albain KS, Swann RS, Rusch VW et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial. Lancet 2009; 374:379-386.
4. van Meerbeeck JP, Kramer GW, Van Schil PE et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007;99:442-450.
5. Bryant AS, Rudemiller K, Cerfolio RJ. The 30- versus 90-day operative mortality after pulmonary resection. Ann Thorac Surg 2010;89:1717-1722; discussion 1722-1723.
6. Eberhardt WEE, Pöttgen C, Gauler TC et al. Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIa(N2)and selected IIIbnon-smallcell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE). J Clin Oncol 2015;33:4194-4201.
7. Chang JY, Senan S, Paul MA et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: A pooled analysis of two randomised trials. Lancet Oncol 2015;16:630-637.
8. Palma D, Visser O, Lagerwaard FJ et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: A population-based time-trend analysis. J Clin Oncol 2010;28:5153-5159.
9. Shirvani SM, Jiang J, Chang JY et al. Comparative effectiveness of 5 treatment strategies for earlystage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys 2012;84:1060-1070.
10. Shirvani SM, Jiang J, Chang JY et al. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg 2014;149:1244-1253.
11. Yu JB, Soulos PR, Cramer LD et al. Comparative effectiveness of surgery and radiosurgery for stage I non-small cell lung cancer. Cancer 2015;121: 2341-2349.
12. Solda F, Lodge M, Ashley S et al. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort. Radiother Oncol 2013;109:1-7.
13. Zheng X, Schipper M, Kidwell K et al. Survival outcome after stereotactic body radiation therapy and surgery for stage i non-small cell lung cancer: A meta-analysis. Int J Radiat Oncol Biol Phys 2014;90: 603-611.
14. Louie AV, Rodrigues GB, Palma DA et al. Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I nonsmall cell lung cancer in Canada. The Oncologist 2014;19:880-885.
15. Blackstone EH, Lauer MS. Caveat emptor: The treachery of work-up bias. J Thorac Cardiovasc Surg 2004;128:341-344.
16. Powell HA, Tata LJ, Baldwin DR et al. Early mortality after surgical resection for lung cancer: an analysis of the English National Lung cancer audit. Thorax 2013;68:826-834.
17. Schroen AT, Petroni GR, Wang H et al. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials 2010;7:312-321.
18. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and agebased disparities. JAMA 2004;291:2720-2726.
19. Fisher B, Bauer M, Margolese R et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985;312:665-673.
20. Taylor KM, Margolese RG, Soskolne CL. Physicians’ reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer. N Engl J Med 1984;310:1363-1367.
21. Torgerson DJ, Roland M. What is Zelen’s design? BMJ 1998;316:606.
22. Schaffner K. Ethically optimizing clinical trials. In: Kadane JB, ed. Bayesian Methods and Ethics in a Clinical Trial Design. Hoboken, NJ: John Wiley & Sons, Inc., 1996:19-63.
23. Powell HA, Jones LL, Baldwin DRet al. Patients’ attitudes to risk in lung cancer surgery: A qualitative study. Lung Cancer 2015;90:358-363.
24. Shaverdian N, Wang P-C, Steinberg M et al.The patient’s perspective on stereotactic body radiation therapy (SBRT) vs. surgery for treatment of early stage non-small cell lung cancer (NSCLC). Lung Cancer 2015;90:230-233.
25. Meyers BF, Puri V, Broderick SR et al. Lobectomy versus stereotactic body radiotherapy for stage I non-small cell lung cancer: Post hoc analysis dressed up as level-1 evidence? J Thorac Cardiovasc Surg 2015;150:468-471.
26. Jones DR. Do we know bad science when we see it? J Thorac Cardiovasc Surg 2015;150:472-473.
27. Ernst A, Anantham D, Eberhardt R et al. Diagnosis of mediastinal adenopathy-real-time endobronchial ultrasound guided needle aspiration versus mediastinoscopy. J Thorac Oncol 2008;3: 577-582.
28. Yasufuku K, Pierre A, Darling G et al. A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer. J Thorac Cardiovasc Surg 2011;142:1393-1400.e1391.
29. Bravata DM, Gienger AL, McDonald KM et al. Systematic review: thecomparative effectiveness of percutaneous coronary interventions and coronary artery bypass graft surgery. Ann Intern Med 2007; 147:703-716.
30. Cao C, Ang SC, Indraratna P et al. Systematic review and meta-analysis of transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis. Ann Cardiothorac Surg 2013;2:10-23.
31. Uematsu M, Shioda A, Suda A et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: A 5- year experience. Int J Radiat Oncol Biol Phys 2001; 51:666-670.
32. Lagerwaard FJ, Verstegen NE, Haasbeek CJ et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage i nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 2012;83:348-353.
33. Nagata Y, Hiraoka M, Shibata T et al. A phase II trial of stereotactic body radiation therapy for operable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group (JCOG0403). Int J Radiat Oncol Biol Phys 2010;78:S27-S28.
34. Ishikura S, Ito Y, Hiraoka M. JCOG Radiation Therapy Study Group: History and achievements. Jpn J Clin Oncol 2011;41:1241-1243.
35. Timmerman RD, Paulus R, Pass HI et al. Rtog 0618: Stereotactic body radiation therapy (SBRT) to treat operable early-stage lung cancer patients. Presented at: ASCO Annual Meeting; May 31-June 4, 2013; Chicago, IL.
36. Onishi H, Shirato H, Nagata Y et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: Can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys 2011;81: 1352-1358.
37. Komiyama T, Onishi K, Shioyama HY et al. Japanese multi-institutional study of stereotactic body radiotherapy for 661 medically operable patients with stage I non-small cell lung cancer. Presented at: International Association for the Study of Lung Cancer, 16th World Conference; September 6-9, 2015; Denver, CO. Oral 19.05.